• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磺脲类药物治疗对2型糖尿病胰岛素抵抗相关机制的影响。

The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes.

作者信息

Kolterman O G, Olefsky J M

出版信息

Diabetes Care. 1984 May-Jun;7 Suppl 1:81-8.

PMID:6376033
Abstract

Insulin resistance is a characteristic feature of patients with type II diabetes mellitus as well as patients with impaired glucose tolerance (IGT). The cause of the insulin resistance in patients with IGT appears to be solely related to a decrease in the number of cellular insulin receptors, causing a decrease in insulin sensitivity. On the other hand, the mechanisms of the insulin resistance in patients with type II diabetes mellitus are heterogeneous; in these subjects a combination of receptor and postreceptor defects exists, and the relative contribution of these two abnormalities to the overall insulin-resistant state differs depending on the severity of the diabetes. In those patients with the greatest degree of fasting hyperglycemia, the postreceptor defect is clearly the predominant abnormality. In addition to resistance to insulin's effects to promote glucose disposal, type II diabetic patients also exhibit a marked increase in the rate of entry of glucose into the circulation from the liver, as manifested by accelerated rates of hepatic glucose production. Sulfonylureas exert potent extrapancreatic effects that partially correct all of the abnormalities present in the type II diabetic state. Thus, after 3 mo of glyburide treatment, glycemic control is markedly improved and this is accompanied by an increase in insulin secretion, no change in cellular insulin receptors, decreased hepatic glucose production rates, and an increase in overall insulin-mediated glucose disposal. After 18 mo of glyburide treatment, an increase in insulin secretion can no longer be demonstrated, whereas insulin binding to receptors is now significantly increased.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

胰岛素抵抗是2型糖尿病患者以及糖耐量受损(IGT)患者的一个特征性表现。IGT患者胰岛素抵抗的原因似乎仅与细胞胰岛素受体数量减少有关,导致胰岛素敏感性降低。另一方面,2型糖尿病患者胰岛素抵抗的机制是异质性的;在这些患者中,存在受体和受体后缺陷的组合,并且这两种异常对整体胰岛素抵抗状态的相对贡献因糖尿病的严重程度而异。在那些空腹血糖升高程度最大的患者中,受体后缺陷显然是主要异常。除了对胰岛素促进葡萄糖代谢作用的抵抗外,2型糖尿病患者还表现出肝脏葡萄糖进入循环的速率显著增加,表现为肝糖生成速率加快。磺脲类药物具有强大的胰腺外作用,可部分纠正2型糖尿病状态下存在的所有异常。因此,在格列本脲治疗3个月后,血糖控制明显改善,同时伴有胰岛素分泌增加、细胞胰岛素受体无变化、肝糖生成速率降低以及整体胰岛素介导的葡萄糖代谢增加。在格列本脲治疗18个月后,不再能证明胰岛素分泌增加,而此时胰岛素与受体的结合显著增加。(摘要截选至250字)

相似文献

1
The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes.磺脲类药物治疗对2型糖尿病胰岛素抵抗相关机制的影响。
Diabetes Care. 1984 May-Jun;7 Suppl 1:81-8.
2
Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus.磺脲类药物可改善非胰岛素依赖型糖尿病患者的胰岛素结合及胰岛素作用。
Diabetes Care. 1984 May-Jun;7 Suppl 1:100-5.
3
Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals.口服磺脲类药物可抑制非胰岛素依赖型糖尿病患者的肝糖生成。
Diabetes Care. 1984 May-Jun;7 Suppl 1:72-80.
4
Sulfonylurea effects on target tissues for insulin.磺脲类药物对胰岛素靶组织的作用。
Diabetes Care. 1984 May-Jun;7 Suppl 1:42-6.
5
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.与主要内分泌疾病相关的继发性糖尿病:新治疗模式的影响
Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26.
6
Insulin and IGF1 receptor function among type II diabetic responders and nonresponders to glyburide.II型糖尿病患者中对格列本脲有反应者和无反应者的胰岛素及IGF1受体功能。
J Lab Clin Med. 1993 Apr;121(4):555-61.
7
The role of diminished beta cell reserve and insulin resistance in secondary sulfonylurea failure of type 2 diabetes mellitus.β细胞储备减少和胰岛素抵抗在2型糖尿病继发性磺脲类药物失效中的作用。
J Med Assoc Thai. 2001 Dec;84(12):1754-62.
8
Subcutaneous microdialysis before and after an oral glucose tolerance test: a method to determine insulin resistance in the subcutaneous adipose tissue in diabetes mellitus.口服葡萄糖耐量试验前后的皮下微透析:一种测定糖尿病患者皮下脂肪组织胰岛素抵抗的方法。
Diabetes Obes Metab. 2005 Sep;7(5):525-35. doi: 10.1111/j.1463-1326.2004.00424.x.
9
Low-dose oral glyburide reduces glucose production rates in patients with impaired fasting glucose.小剂量口服格列本脲可降低空腹血糖受损患者的葡萄糖生成率。
Metabolism. 2003 Apr;52(4):407-12. doi: 10.1053/meta.2003.50068.
10
Pancreatic beta-cell function and insulin sensitivity in japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus.日本糖耐量受损和新诊断2型糖尿病患者的胰岛β细胞功能及胰岛素敏感性
Metabolism. 2003 Apr;52(4):476-81. doi: 10.1053/meta.2003.50078.

引用本文的文献

1
The role of sulphonylureas in the management of type 2 diabetes mellitus.磺脲类药物在2型糖尿病管理中的作用。
Drugs. 2004;64(12):1339-58. doi: 10.2165/00003495-200464120-00006.
2
Insulin secretion and insulin sensitivity defects are a common feature of mild, clinically homogeneous, recently diagnosed type II (non-insulin-dependent) diabetics.胰岛素分泌及胰岛素敏感性缺陷是新近诊断出的轻度、临床症状均一的II型(非胰岛素依赖型)糖尿病患者的常见特征。
Acta Diabetol Lat. 1986 Jul-Sep;23(3):215-25. doi: 10.1007/BF02624707.
3
Diet only or diet and sulfonylureas in mild type II diabetes (NIDDM)? Pathophysiologic and therapeutic implications.
单纯饮食治疗还是饮食与磺脲类药物联合治疗轻度II型非胰岛素依赖型糖尿病?病理生理及治疗意义。
Acta Diabetol Lat. 1988 Oct-Dec;25(4):289-97. doi: 10.1007/BF02581127.
4
Acute effect of glibenclamide upon red cell transglutaminase activity in diabetic patients.格列本脲对糖尿病患者红细胞转谷氨酰胺酶活性的急性影响。
J Endocrinol Invest. 1987 Dec;10(6):565-8. doi: 10.1007/BF03346995.
5
Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.磺酰脲类抗糖尿病药物。其临床药理学与合理治疗应用的最新进展。
Drugs. 1989 Jan;37(1):58-72. doi: 10.2165/00003495-198937010-00004.
6
Factors for development of secondary failure to sulfonylurea drugs in non-insulin-dependent diabetes mellitus.非胰岛素依赖型糖尿病患者磺脲类药物继发失效的相关因素
Acta Diabetol Lat. 1991 Jan-Mar;28(1):91-8. doi: 10.1007/BF02732118.
7
Pharmacokinetic optimisation of oral hypoglycaemic therapy.口服降糖治疗的药代动力学优化
Clin Pharmacokinet. 1991 Oct;21(4):308-17. doi: 10.2165/00003088-199121040-00006.